EGFR and neoplasm: This acquisition may lead to increased mutant allele transcription and EGFR gene activity under EGFR‐TKI treatment pressure [25, 26], manifesting as pronounced genome instability and genome‐wide hypomethylation, ultimately affecting tumor cell sensitivity to EGFR‐TKI [21].